Lipella raises $726k in fourth closing of Series B preferred offering at $2.51 conversion

LIPELLA PHARMACEUTICALS INC.

Gross proceeds of $726,000 from sale of 7,260 Series B shares convertible into 289,241 common shares at $2.51/share.
Net proceeds of $602,580; Spartan Capital received $123,420 in fees, 84,700 Series C voting preferred shares and warrants for 28,924 common shares.
CEO Jonathan Kaufman granted irrevocable voting power over Spartan's issued shares via proxy.
Proceeds from the offering to be used for working capital and general corporate purposes.

item 1.01 item 3.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001753926-25-000425
form_type: 8-K
ticker: LIPO
cik: 0001347242
company_name: LIPELLA PHARMACEUTICALS INC.
filed_at: 2025-03-11T23:59:59+00:00
discovered_at: 2026-05-14T18:03:03.405805+00:00
generated_at: 2026-05-24T23:23:11.738510+00:00
sec_items: ["1.01", "3.02", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001753926-25-000425
json_url: https://secwatch.observer/filing/0001753926-25-000425.json
markdown_url: https://secwatch.observer/filing/0001753926-25-000425.md
text_url: https://secwatch.observer/filing/0001753926-25-000425.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1347242/000175392625000425/0001753926-25-000425-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1347242/000175392625000425/g084727_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001753926-25-000425

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.